Company Profile

Mapp Biopharmaceutical Inc
Profile last edited on: 9/21/2022      CAGE: 417U0      UEI: M9V9QTHR1H28

Business Identifier: Pharmaceuticals for prevention and treatment of infectious diseases such as ZMapp for Ebola
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6160 Lusk Boulevard Suite C105
San Diego, CA 92121
   (858) 625-0335
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Mapp Biopharmaceuticals is involved in development of pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio. Flying primarily under the radar, in August 2014 the firm was projected into the headlines over the use of their as yet unapproved treatment - ZMappTM - on two US citizen who had contracted the often fatal Ebola virus. ZMappTM is the result of a collaboration between Mapp Biopharmaceutical, Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC). ZMappTM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimized cocktail combining the best components of MB-°©?003 (Mapp) and ZMAb (Defyrus/PHAC). ZMappTM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available. Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA. Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible. A more recent MAPP achievment has been the award in Summer 2019 of an advanced R&D contract for $16.5 million with options for an additional $30.0 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 though the completion of a Phase 1 clinical trial - work much needed to develop therapeutics for infected individuals and for the Strategic National Stockpile.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $3,347,713
Project Title: Development of Highly Potent Human Monoclonals for RSV Immunoprophylaxis
2020 2 CBD $1,149,033
Project Title: Marburg Virus Prophylactic Medical Countermeasure
2019 2 NIH $6,524,870
Project Title: An Immunoprotectant for Marburg Virus
2018 2 NIH $725,000
Project Title: Direct Sequencing of Antibodies of the Influenza Immune Response
2017 1 NIH $255,046
Project Title: Direct Sequencing of Serum Antibodies After Infection

Key People / Management

  Kevin J Whaley -- CEO

  Ronald Aimes -- Vice President of Nonclinical Development

  Adrian Guthals

  Andrew C Hiatt -- CSO

  Larry Zeitlin -- President